Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644594 | 0.90 | GPR119 (0.32) | GPR119 | |
| SCHEMBL21136381 | 0.89 | GPR119 (0.31) | GPR119NPSR1 | |
| SCHEMBL31406969 | 0.84 | GPR119 (0.33) | GPR119AURKARPS6KB1NPSR1 | |
| SCHEMBL17465415 | 0.84 | GPR119 (0.33) | GPR119AURKARPS6KB1NPSR1 | |
| SCHEMBL17465433 | 0.84 | GPR119 (0.33) | GPR119AURKARPS6KB1NPSR1 | |
| SCHEMBL19644588 | 0.83 | CYP3A4 (0.33) | GPR119AURKARPS6KB1CYP3A4NPSR1 | |
| SCHEMBL17465422 | 0.82 | GPR119 (0.32) | GPR119AURKARPS6KB1NPSR1 | |
| SCHEMBL17465421 | 0.82 | GPR119 (0.32) | GPR119AURKARPS6KB1NPSR1 | |
| SCHEMBL29788385 | 0.82 | — | — | |
| SCHEMBL17465411 | 0.82 | NPSR1 (0.32) | GPR119AURKARPS6KB1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023650-A1 | 4'-SUBSTITUTED-FURO[3,2-D]PYRIMIDINE AND -PYRROLO[3,2- D]PYRIMIDINE DERIVATIVES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3174870-B1 | THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10179794-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180072755-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9828388-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179794-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | DPYD, TYMS, TYMP | GPR119 3447/4885AURKA 2189/4885RPS6KB1 4086/4885 |
| US-20180072755-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | GPR119 3447/4885AURKA 2189/4885RPS6KB1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.